profit from every $100 of sales.
$0$100
Structure Therapeutics
$20.00+0.81% today
-42.0% in 1 year
1-year low $19.081-year high $93.79
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Structure Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$141 million of profit last year.
SalesProfit
Structure Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Structure Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Structure Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -53 | -103 | -158 | -187 | |
| -52 | -102 | -157 | -185 | |
| -51 | -90 | -123 | -141 | |
| -1.38 | -2.43 | -2.14 | -1.99 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 98 | 482 | 903 | 1,584 |
| Cash | 26 | 130 | 170 | 800 |
| Total debt | 0 | 5 | 4 | 6 |
| Total liabilities | 213 | 29 | 38 | 68 |
| -115 | 453 | 865 | 1,516 | |
| 38 | 37 | 57 | 71 | |
| – | -17.7% | -14.4% | -9.7% | |
| 44.6% | -19.8% | -14.2% | -9.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -46 | -79 | -117 | -222 | |
| 0 | 2 | 1 | 4 | |
| -46 | -82 | -118 | -226 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 8 | 19 | 29 |
Valuation
- –
- –
- –
- 1.9×
- –
- –
- –
- -15.8%
- -9.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -14.4%
- 12.8%
- -15.1%
- -11.3%
- -14.5%
- –
Growth
- –
- –
- −91.5%
- –
- +12.8%
Financial health
- 1.6×
- 0.00
- 0.4%
- –
- 26.16
- 26.16
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 952
Bottom 20%of 883
Bottom 6%of 987
What analysts expect
- Average price target
- $114.75
- Range
- $90.00 – $145.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.35 | -0.39 | +10.3% |
| Feb 26, 2026 | -0.49 | -0.35 | −40.0% |
| Nov 6, 2025 | -0.37 | -0.36 | −2.8% |
| Aug 6, 2025 | -0.36 | -0.28 | −28.6% |
| May 8, 2025 | -0.27 | -0.24 | −12.5% |
| Feb 27, 2025 | -0.22 | -0.23 | +4.3% |
| Nov 13, 2024 | -0.20 | -0.19 | −5.3% |
| Aug 8, 2024 | -0.18 | -0.23 | +21.7% |
News
Anthropic's IPO Keeps Founders in Control Through a "Founder LLC" Voting StructureYahoo Finance · Oct 26, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
55No pass
Philip Fisher
36No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
33No pass
Questions about Structure Therapeutics
Is Structure Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Structure Therapeutics AI analysis
What does Structure Therapeutics do?
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. It is in Biotechnology, based in South San Francisco, CA, United States, with 220 employees.
Does Structure Therapeutics pay a dividend?
No. Structure Therapeutics does not pay a dividend at the moment.
Is Structure Therapeutics stock halal?
No. Structure Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 56% of its market value, at or above the 33% limit. How we check
How has Structure Therapeutics stock done over the past year?
Down 42.0% over the past twelve months, to $20.00. It traded between $19.08 and $93.79 and is 78.7% below its high.
Who are Structure Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Structure Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.